Search - tctmd.com

Displaying 61 - 80 of 165

Sort: Relevancy | Date

Presentation TCT 2017

UPLMPCI How to Use Evidence and Precision Medicine to Optimize Outcomes, a Case Example

Presenter: Ayman Abou El Magd, Mohamed Ahmed Sobhy, Hany Ragy

October 29, 2017

Presentation TCT 2017

Forty Years After the First PCI, Where Are We and Where Are We Headed?

Presenter: Alejandro Cherro, Alfredo E. Rodriguez, Spencer B. King III

October 29, 2017

Presentation TVT 2017

Hemodynamic Trends on Serial Echocardiograms After TAVR: Comprehensive 5-Year Analyses From the PARTNER 1 Trials

Presenter: Martin B. Leon, Hendrik Treede, Philippe Pibarot

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TCT 2016

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Ganesh Manoharan

November 01, 2016

Presentation TCT 2016

Case Conclusion: How Did We Treat Our Patient?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

Think Twice: BRS First

Presenter: George D. Dangas, Fabio Felice Tarantino, Francesco Saia

November 01, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

Presenter: George D. Dangas, Fabio Felice Tarantino, Massimo Fineschi

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Case 4:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, Jamshed J. Dalal

October 31, 2016

Presentation TCT 2016

Case 3:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, Rabin dra Nath Chakraborty

October 31, 2016

Presentation TCT 2016

Case 1:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, M.S. Hiremath

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TVT 2016

PARTNER Echocardiography Observations on Valve Durability

Presenter: Rebecca T. Hahn

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

Advertisement

UPLMPCI How to Use Evidence and Precision Medicine to Optimize Outcomes, a Case Example

Forty Years After the First PCI, Where Are We and Where Are We Headed?

Hemodynamic Trends on Serial Echocardiograms After TAVR: Comprehensive 5-Year Analyses From the PARTNER 1 Trials

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Case Conclusion: How Did We Treat Our Patient?

Think Twice: BRS First

Choose a Drug-Eluting Stent: Heres Why

Case Introduction: What Device(s) to Choose in a Patient With NSTE-ACS?

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Case 4:

Case 3:

Case 1:

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

PARTNER Echocardiography Observations on Valve Durability

Study Design for the PARTNER 3 Low-Risk Trial

Highlights From PARTNER 2A in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content